Qilu Pharmaceutical's ophthalmic medication pipeline has ushered in a new member!

【Pharmaceutical Network Enterprise News】Driven by the popularization of electronic products and the aging of the population, the domestic ophthalmic market is continuing to grow, and the industry development space is becoming more and more broad
.
Affected by this, this field has gradually become the focus of the strategic layout of
many domestic pharmaceutical companies.
At the same time, a large number of companies continue to come with good news
in ophthalmic medicine.
News on January 12, Qilu Pharmaceutical issued an announcement that the company's brimonidine timolol eye drops (including multi-dose and single-dose two packaging specifications) were approved for marketing by the National Medical Products Administration and deemed to have passed the consistency evaluation, of which the single-dose packaging is exclusively listed
in China.
It is understood that timolol and brimonidine are commonly used drugs to reduce intraocular pressure, as a compound preparation of the two, brimonidine timolol eye drops can further increase the efficacy of reducing intraocular pressure, play a complementary role, and compound preparations can reduce the frequency of administration and improve medication compliance
.
Brimonidine timolol eye drops from Qilu Pharmaceutical, clinically used to reduce elevated intraocular pressure
in adult patients with open-angle glaucoma or hyperototropia.
The two approved packaging products have their own advantages
.
Among them, the composition of multi-dose prescriptions is consistent with the original product, and the price is cheaper; A single dose does not contain preservatives, which can avoid the adverse effects caused by long-term medication in glaucoma patients, and is more convenient to carry for one-time use
.
Over the years, in fact, Qilu Pharmaceutical has been laying out excellent varieties in the field of ophthalmology, deeply cultivating the ophthalmic product line, and also established a special ophthalmology division
in 2021.
At present, the company's ophthalmic drugs have covered the main treatment areas such as eye anti-infection, ocular postoperative inflammation, glaucoma, anti-allergy, and visual fatigue (dry eye), which can provide effective solutions
for common clinical ophthalmic diseases.
For example, in June 2022, Qilu Pharmaceutical's single-dose diquafosso sodium eye drops were approved by the National Medical Products Administration and deemed to have passed the consistency evaluation, which is the first preservative-free diquafosso sodium eye drops in China
.
In addition, it also submitted the marketing authorization application for aflibercept intraocular injection solution in April last year, which was accepted by the Drug Review Center of the State Food and Drug Administration, which is also the first biosimilar declared in China for this variety
.
Of course, in addition to ophthalmic drugs, Qilu Pharmaceutical's research scope also covers tumors, cardiovascular and cerebrovascular, anti-infection, mental system, nervous system and other disease fields
.
In recent years, the company has established a rich pipeline of innovative drug R&D through the combination of independent R&D and introduction
.
For example, in 2021, Qilu Pharmaceutical has two projects that won the second prize of the National Science and Technology Progress Award, and has won a total of 7 projects, and has successively undertaken more than 40 major national science and technology special projects for major new drug creation, and a number of raw materials and preparation products have successfully passed the certification
of drug regulatory authorities in many countries in Europe and the United States.
The industry expects that in the future, through the continuous introduction of international advanced technology and outstanding talents, and improving its own R&D and innovation level, Qilu Pharmaceutical is expected to usher in more new breakthroughs in many fields, and overcome obstacles in many pharmaceutical directions such as oncology, cardiovascular and cerebrovascular, and ophthalmology, and accelerate the seizure of the commanding heights
of science and technology.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.